Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.
about
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsPharmacological treatments for non-alcohol related fatty liver disease (NAFLD): a network meta-analysisNon-alcoholic fatty liver disease: what the clinician needs to know.Moro orange juice prevents fatty liver in miceThe Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic BackgroundNAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDNAFLD and Chronic Kidney DiseaseGene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise reviewBiomarker-Based Approaches for Assessing Alcohol Use DisordersTreatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight LossDoes Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?Comorbidities and Metabolic Derangement of NAFLDLiver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment StrategyManagement of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver diseaseDietary habits and behaviors associated with nonalcoholic fatty liver diseaseCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateAlcoholic and non-alcoholic steatohepatitisNonalcoholic fatty liver disease and vascular disease: state-of-the-art.Nonalcoholic fatty liver disease - A multisystem disease?Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVCardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature reviewOxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisObesity and non-alcoholic fatty liver disease: Disparate associations among Asian populationsγ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes StudyLiraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialHepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.NAFLD and liver transplantation: Current burden and expected challenges.Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Cost-utility analysis of nonalcoholic steatohepatitis screening.Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.Controversies in the Diagnosis and Management of NAFLD and NASH.Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.Inflammation in nonalcoholic steatohepatitis.Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
P2860
Q22299426-24DEF2DB-E356-4067-AB7C-C4CA9E369C2DQ24186865-0725A18F-3991-488C-B302-1816594FF419Q24563068-C7AAC4B2-0753-4EAB-9782-99498CC4F5B3Q24622681-0E7ACE64-C3A3-4945-93C9-74F2D2FA0F7CQ26744380-F374DA13-CCD0-420A-9FDA-DCB9D684AEDDQ26750955-3CE86F71-5261-4824-B7C0-A2A16C885811Q26752487-F5CEB289-9F00-42E0-9202-BF30D32ACDC2Q26752759-08BF3A93-D1C0-4D1F-A76A-04C7AB52CF42Q26766459-3E436FEB-7E9E-4466-A089-3F087CF9C0E6Q26772931-58D5E84B-7AB6-454A-A3B7-79509CF34A19Q26775632-F1C9E7B2-C8A7-43EF-9088-DED7E5394E2AQ26776043-05F60141-1FF8-4EFA-8A4B-E8C1C1DF691FQ26777147-0B598F08-8ED7-4B63-B18E-F6E56B2308E2Q26780252-C5E87957-CC75-484A-AE7C-5C0AE26268CBQ26781753-C87A5AD2-CBA7-4088-8F40-10D14429132DQ26827665-E8E4D239-9E72-42B6-AF60-6FF38222B9E4Q26830594-5B3E0A4D-5061-4420-BF01-50771D86C435Q26997059-6C73C5A3-9167-49F5-A8EE-C38B7C5CC22CQ27000153-870B292A-17F1-4375-A4A1-966E2E960A7DQ27692035-36BFD715-3862-4DBE-83E2-76FFADBBB597Q28079077-DF0DD903-4FE5-4E82-82EE-5B0A2B0484F4Q28079826-5D6FDCB3-71C4-4FD0-A813-865870467723Q28081066-0BD99C2C-E7D0-4947-9F73-D1A8102197C4Q28084150-85F868CC-EAA9-425E-A7C2-F1870E037022Q28386598-30A6E47C-5F23-425F-8D8C-5D5ECBDD4DD0Q28648219-0BE35F75-2959-459B-AA3E-741972151CA2Q28661700-A389E875-49B6-4BBC-A08D-B515C8AC7324Q30234574-E6AB234F-A02F-43CE-AF85-0EFFA5E1CF8FQ30248646-4166DC1E-49B6-402A-A1EB-497E87BBCAFAQ30249400-864381DE-1DBA-4463-84A6-DF809F6B71D7Q30382278-E645D442-5A71-425D-8B66-75EBBAA1E82DQ30385602-CBDB316B-5FDF-4382-A569-634C2B8CA1A1Q30396916-798F0E21-EAB0-4766-843D-F581966A9852Q30401022-22A0035D-ACCA-4393-B6F7-5EC15C7ADCFEQ30412296-832E164D-3FD1-4D2F-84A4-6D0E22189D2BQ30435948-7ED232E6-58B3-4B91-ADBB-20CF0C8761EFQ30453231-D35B9566-1F5C-426E-B5DA-748E6FE76B91Q30464608-391EE831-777F-4369-B4DD-108CD6F1F242Q30622511-646B1735-7D61-4B84-ABA5-F1F334E5F587Q33579420-47BE92B2-0B81-452F-B6A2-6BDA13A035C2
P2860
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Decreased survival of subjects ...... ts during a 28-year follow-up.
@en
type
label
Decreased survival of subjects ...... ts during a 28-year follow-up.
@en
prefLabel
Decreased survival of subjects ...... ts during a 28-year follow-up.
@en
P2093
P356
P1433
P1476
Decreased survival of subjects ...... sts during a 28-year follow-up
@en
P2093
Cecilia Söderberg
Greger Lindberg
Hans Glaumann
Joel Marmur
Johan Askling
Rolf Hultcrantz
P304
P356
10.1002/HEP.23314
P407
P50
P577
2010-02-01T00:00:00Z